Together, these data demonstrate that alanine could be used to target glutamine dependency in SMARCA4/2-deficient cancer cells by suppressing SLC38A2-mediated glutamine import and consequently, inhibiting glutaminolysis and OXPHOS. Here, SLC38A2 is linked to cancer.